Lotfi Benboubker

Teclistamab in Relapsed or Refractory Multiple Myeloma

Philippe Moreau, Alfred L. Garfall, Niels W.C.J. van de Donk et al. · New England Journal of Medicine · 2022 · 1.1K citations · Full text

Medicine, Hematology, Immunology +17

Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study

Philippe Moreau, Michel Attal, Cyrille Hulin et al. · The Lancet · 2019 · 953 citations · Full text

Medicine, Hematology, Pharmacotherapy +14

Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myelome

Hervé Avet‐Loiseau, Michel Attal, Philippe Moreau et al. · Blood · 2007 · 905 citations · Full text

Medicine, Genetics, Hematology +15

Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99–06): a randomised trial

Thierry Façon, Jean Yves Mary, Cyrille Hulin et al. · The Lancet · 2007 · 870 citations

Medicine, Hematology, Oncology +17

Lenalidomide and Dexamethasone in Transplant-Ineligible Patients with Myeloma

Lotfi Benboubker, Meletios Α. Dimopoulos, Angela Dispenzieri et al. · New England Journal of Medicine · 2014 · 786 citations · Full text

Medicine, Oncology, Pharmacotherapy +11